RedHill Biopharma (RDHL) announced that the New York Supreme Court’s summary judgment in favor of RedHill against Kukbo Co. is now final and eligible for enforcement and foreign recognition, with no further appeal permissible following expiry of the appeal period. The Court has awarded more than $10.5M in total to RedHill, comprised of the main judgment of approximately $8.6M, now final and eligible for enforcement, and the award for legal fees and expenses of approximately $1.9M (both include the principal amounts and accrued interest, to date) which remains subject to appeal until March 13, 2026. 9% annual statutory interest continues to accrue on both awards. In addition, RedHill has secured a Korean court attachment grant against Kukbo aimed at preventing Kukbo from disposing of assets prior to judgment enforcement.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost
- RedHill Biopharma Amends Purchase Agreement with Alumni Capital
- RedHill Biopharma Secures $4 Million Investment and U.S. Partnership for Talicia
- RedHill Biopharma signs strategic partnership with Cumberland
- RedHill Biopharma Secures $1.8 Million Middle East Deal for Talicia